AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
ACI-24.060 elicited an anti-Abeta antibody response in ABATE’s first, low dose cohort
ACI-24.060 was generally well tolerated with no safety concerns observed
With these findings, dosing in the second, higher dose Alzheimer’s cohort has begun
Screening of cohort of study participants with Down syndrome also cleared to begin
Further safety and immunogenicity findings from ABATE cohorts expected in H2 2023
Initial data on amyloid plaque reduction measured via PET imaging anticipated in 2024
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.